Vertex Pharmaceuticals Income (Loss) from Continuing Operations Before Income Taxes, Foreign remained flat by 0.0% to $455.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.6%, from $404.55M to $455.50M. Over 2 years (FY 2023 to FY 2025), Income (Loss) from Continuing Operations Before Income Taxes, Foreign shows an upward trend with a 18.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate successful international expansion and global market demand.
The pre-tax income or loss generated from operations conducted outside the company's home country. This reflects the pro...
Standard geographic segment reporting for multinational corporations.
ms_income_before_tax_foreign| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.29B | $1.62B | $1.82B |
| YoY Change | — | +25.4% | +12.6% |